The Prevalence of Mixed Hepatitis C Virus Genotype Infection and Its Effect on the Response to Direct-Acting Antivirals Therapy

Intervirology ◽  
2019 ◽  
Vol 62 (1) ◽  
pp. 23-29
Author(s):  
Kazuhiko Hayashi ◽  
Kosuke Tachi ◽  
Yuko Shimizu ◽  
Kenichi Nagano ◽  
Yoji Ishizu ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Direct Acting Antivirals ◽  
Virus Genotype ◽  
Direct Acting ◽  
Genotype Infection

scholarly journals Analysis of hepatitis C virus genotype 3 resistance to direct acting antivirals

2019 ◽  
Vol 1 (1A) ◽  
Author(s):  
Guilherme Rodrigues Fernandes Campos ◽  
João Paulo Vilela Rodrigues ◽  
Cintia Bittar ◽  
Bruna Forte Aguiar ◽  
Silvana Gama Florêncio Chacha ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Direct Acting Antivirals ◽  
Genotype 3 ◽  
Virus Genotype ◽  
Direct Acting

scholarly journals A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir

2020 ◽  
Author(s):  
Guilherme Rodrigues Fernandes Campos ◽  
Joseph Ward ◽  
Shucheng Chen ◽  
Cintia Bittar ◽  
João Paulo Vilela Rodrigues ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Acquired Resistance ◽  
Direct Acting Antivirals ◽  
Genotype 3 ◽  
Virus Genotype ◽  
High Level ◽  
Direct Acting ◽  
Replication Fitness ◽  
Modest Effect

Hepatitis C virus (HCV) genotype 3 presents a high level of both baseline and acquired resistance to direct-acting antivirals (DAAs), particularly those targeting the NS5A protein. To understand this resistance we studied a cohort of Brazilian patients treated with the NS5A DAA, daclatasvir and the nucleoside analogue, sofosbuvir. We observed a novel substitution at NS5A amino acid residue 98 [serine to glycine (S98G)] in patients who relapsed post-treatment. The effect of this substitution on both replication fitness and resistance to DAAs was evaluated using two genotype 3 subgenomic replicons. S98G had a modest effect on replication, but in combination with the previously characterized resistance-associated substitution (RAS), Y93H, resulted in a significant increase in daclatasvir resistance. This result suggests that combinations of substitutions may drive a high level of DAA resistance and provide some clues to the mechanism of action of the NS5A-targeting DAAs.

Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir

2013 ◽  
Vol 58 (4) ◽  
pp. 646-654 ◽  
Author(s):  
Yoshiyasu Karino ◽  
Joji Toyota ◽  
Kenji Ikeda ◽  
Fumitaka Suzuki ◽  
Kazuaki Chayama ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Direct Acting Antivirals ◽  
Virus Genotype ◽  
Genotype 1B ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document